Danuta Szkutnik-Fiedler, Edyta Szałek, Filip Otto, Andrzej Czyrski, Marta Karaźniewicz-Łada, Anna Wolc, Edmund Grześkowiak, Konrad Lewandowski, Agnieszka Karbownik
BACKGROUND: Regorafenib is used in the treatment of colorectal cancer and hepatocellular carcinoma. Due to the co-morbidity of hyperlipidemia in these conditions, statins, including atorvastatin, are used as potential adjuvant therapy agents. Both regorafenib and atorvastatin are metabolized by CYP3A4. In addition, atorvastatin is a P-gp and BCRP substrate, whereas regorafenib and its active metabolites M-2 and M-5 are inhibitors of these transporters. Hence, the concomitant use of both drugs may increase the risk of a clinically significant drug-drug interaction...
April 18, 2024: Pharmacological Reports: PR